Click for best price
NonAlcoholic Steatohepatitis NASH Drugs Market Size, Share 2022
Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
This report contains market size and forecasts of Non-Alcoholic Steatohepatitis (NASH) Drugs in Global, including the following market information:
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-Alcoholic Steatohepatitis (NASH) Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Vitamin E & Pioglitazone Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-Alcoholic Steatohepatitis (NASH) Drugs include AstraZeneca, Conatus Pharmaceuticals, Enzo Biochem, Galmed Pharmaceuticals, Genfit, Gilead, Horizon Pharma, Immuron and Intercept Pharmaceuticals and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Alcoholic Steatohepatitis (NASH) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Percentages, by Type, 2021 (%)
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacy
Online Provider
Retail Pharmacy
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Alcoholic Steatohepatitis (NASH) Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-Alcoholic Steatohepatitis (NASH) Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
| Report Attributes |
Report Details |
| Report Title |
Non-Alcoholic Steatohepatitis (NASH) Drugs Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
64 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Overall Market Size
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size: 2021 VS 2028
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players in Global Market
3.2 Top Global Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Ranked by Revenue
3.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Companies
3.4 Top 3 and Top 5 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-Alcoholic Steatohepatitis (NASH) Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Drugs Players in Global Market
3.6.1 List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Markets, 2021 & 2028
4.1.2 Vitamin E & Pioglitazone
4.1.3 Obeticholic Acid (OCA)
4.1.4 Elafibranor
4.1.5 Selonsertib & Cenicriviroc
4.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue & Forecasts
4.2.1 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2017-2022
4.2.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2023-2028
4.2.3 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2021 & 2028
5.1.2 Hospital Pharmacy
5.1.3 Online Provider
5.1.4 Retail Pharmacy
5.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue & Forecasts
5.2.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2017-2022
5.2.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2023-2028
5.2.3 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2021 & 2028
6.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue & Forecasts
6.2.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2017-2022
6.2.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2023-2028
6.2.3 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2017-2028
6.3.2 US Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.3.3 Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.3.4 Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2017-2028
6.4.2 Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.4.3 France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.4.4 U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.4.5 Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.4.6 Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.4.7 Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.4.8 Benelux Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2017-2028
6.5.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.5.3 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.5.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.5.5 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.5.6 India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2017-2028
6.6.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.6.3 Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2017-2028
6.7.2 Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.7.3 Israel Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.7.4 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
6.7.5 UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2017-2028
7 Players Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Corporate Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.1.4 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2017-2022)
7.1.5 AstraZeneca Key News
7.2 Conatus Pharmaceuticals
7.2.1 Conatus Pharmaceuticals Corporate Summary
7.2.2 Conatus Pharmaceuticals Business Overview
7.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.2.4 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2017-2022)
7.2.5 Conatus Pharmaceuticals Key News
7.3 Enzo Biochem
7.3.1 Enzo Biochem Corporate Summary
7.3.2 Enzo Biochem Business Overview
7.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.3.4 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2017-2022)
7.3.5 Enzo Biochem Key News
7.4 Galmed Pharmaceuticals
7.4.1 Galmed Pharmaceuticals Corporate Summary
7.4.2 Galmed Pharmaceuticals Business Overview
7.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.4.4 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2017-2022)
7.4.5 Galmed Pharmaceuticals Key News
7.5 Genfit
7.5.1 Genfit Corporate Summary
7.5.2 Genfit Business Overview
7.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.5.4 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2017-2022)
7.5.5 Genfit Key News
7.6 Gilead
7.6.1 Gilead Corporate Summary
7.6.2 Gilead Business Overview
7.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.6.4 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2017-2022)
7.6.5 Gilead Key News
7.7 Horizon Pharma
7.7.1 Horizon Pharma Corporate Summary
7.7.2 Horizon Pharma Business Overview
7.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.7.4 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2017-2022)
7.7.5 Horizon Pharma Key News
7.8 Immuron
7.8.1 Immuron Corporate Summary
7.8.2 Immuron Business Overview
7.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.8.4 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2017-2022)
7.8.5 Immuron Key News
7.9 Intercept Pharmaceuticals
7.9.1 Intercept Pharmaceuticals Corporate Summary
7.9.2 Intercept Pharmaceuticals Business Overview
7.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.9.4 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2017-2022)
7.9.5 Intercept Pharmaceuticals Key News
7.10 Novo Nordisk
7.10.1 Novo Nordisk Corporate Summary
7.10.2 Novo Nordisk Business Overview
7.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.10.4 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2017-2022)
7.10.5 Novo Nordisk Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Opportunities & Trends in Global Market
Table 2. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers in Global Market
Table 3. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints in Global Market
Table 4. Key Players of Non-Alcoholic Steatohepatitis (NASH) Drugs in Global Market
Table 5. Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-Alcoholic Steatohepatitis (NASH) Drugs Product Type
Table 9. List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2023-2028
Table 30. AstraZeneca Corporate Summary
Table 31. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 32. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), (2017-2022)
Table 33. Conatus Pharmaceuticals Corporate Summary
Table 34. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 35. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Enzo Biochem Corporate Summary
Table 37. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 38. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), (2017-2022)
Table 39. Galmed Pharmaceuticals Corporate Summary
Table 40. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 41. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Genfit Corporate Summary
Table 43. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 44. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), (2017-2022)
Table 45. Gilead Corporate Summary
Table 46. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 47. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), (2017-2022)
Table 48. Horizon Pharma Corporate Summary
Table 49. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 50. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Immuron Corporate Summary
Table 52. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 53. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), (2017-2022)
Table 54. Intercept Pharmaceuticals Corporate Summary
Table 55. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 56. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), (2017-2022)
Table 57. Novo Nordisk Corporate Summary
Table 58. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 59. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Segment by Type in 2021
Figure 2. Non-Alcoholic Steatohepatitis (NASH) Drugs Segment by Application in 2021
Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2021
Figure 8. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
Figure 12. US Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
Figure 24. China Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
